Condition: Heart Failure Acute · Sponsor: Zuyderland Medisch Centrum
Acutely decompensated heart failure (ADHF) is highly prevalent and has a high (financial) burden on the health care system. Treatment often consists of the administration of IV decongestive agents. Adequate dosing is difficult due to varying diuretic resistance and inadequate parameters to evaluate the response. Urine sodium is a promising biomarker to evaluate the diuretic response. It is hypothesized that a tailored, urine sodium guided diuretic algorithm will result in faster and more complete decongestion and therefore lead to better survival (in terms of mortality and heart failure events) while being non-inferior in terms of safety (mainly regression of kidney function).
This description comes directly from the study's public registry record.
Sandra van Wijk, MD, PhD · 088 - 459 9701 · s.vanwijk@zuyderland.nl
Mick Hoen, MD · 088 - 459 9701 · m.hoen@zuyderland.nl
Always discuss trial participation with your own doctor first.
| Zuyderland MC | Heerlen, Limburg, Netherlands | Recruiting |
| Amphia ziekenhuis | Breda, North Brabant, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06092437